argenx’s (ARGX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of argenx (NASDAQ:ARGX) in a research note published on Wednesday,Benzinga reports. They currently have a $617.00 price target on the stock.

Several other research firms have also commented on ARGX. Oppenheimer boosted their price target on argenx from $560.00 to $646.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. William Blair raised argenx from a “market perform” rating to an “outperform” rating in a research report on Friday, November 1st. Baird R W lowered argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. Guggenheim upped their target price on argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Finally, Wolfe Research raised argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 target price on the stock in a research report on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $630.42.

argenx Stock Up 1.5 %

Shares of NASDAQ ARGX opened at $605.92 on Wednesday. The business has a fifty day simple moving average of $556.37 and a two-hundred day simple moving average of $486.73. The firm has a market cap of $36.23 billion, a PE ratio of -693.08 and a beta of 0.61. argenx has a twelve month low of $327.73 and a twelve month high of $611.22.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. The business had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same period in the previous year, the company posted ($1.25) EPS. On average, research analysts expect that argenx will post 2.2 earnings per share for the current year.

Institutional Trading of argenx

Hedge funds have recently modified their holdings of the stock. J.Safra Asset Management Corp boosted its stake in shares of argenx by 590.0% in the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after buying an additional 59 shares during the last quarter. Blue Trust Inc. boosted its position in argenx by 620.0% during the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after purchasing an additional 62 shares in the last quarter. GAMMA Investing LLC boosted its position in argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after purchasing an additional 40 shares in the last quarter. Cromwell Holdings LLC boosted its position in argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after purchasing an additional 66 shares in the last quarter. Finally, Point72 Hong Kong Ltd purchased a new position in argenx during the second quarter worth approximately $76,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.